News | May 08, 2024
WACKER expands production capacity for biopharmaceuticals in San Diego
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
New solvent-free micronization technology expanded at the Darmstadt site in Germany
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Additional capacity broadens Grace’s fine chemical capabilities for API production
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
Atlas AI combines NVIDIA BioNeMo cloud APIs for intelligent chemical and protein design
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
Almost 300 million people globally have chronic hepatitis B
The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in other important Latin American countries
Increased capability to produce medicines for challenging diseases including cancer
Subscribe To Our Newsletter & Stay Updated
